Published in Brain on February 15, 2010
Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. Ann Neurol (2011) 2.84
Association of cerebrospinal fluid β-amyloid 1-42, T-tau, P-tau181, and α-synuclein levels with clinical features of drug-naive patients with early Parkinson disease. JAMA Neurol (2013) 1.83
Parkinson's disease dementia: convergence of α-synuclein, tau and amyloid-β pathologies. Nat Rev Neurosci (2013) 1.82
Cerebrospinal fluid lysosomal enzymes and alpha-synuclein in Parkinson's disease. Mov Disord (2014) 1.76
CSF Aβ(42) and tau in Parkinson's disease with cognitive impairment. Mov Disord (2010) 1.71
Priorities in Parkinson's disease research. Nat Rev Drug Discov (2011) 1.66
α-Synuclein in Parkinson's disease. Cold Spring Harb Perspect Med (2012) 1.62
SNCA variant associated with Parkinson disease and plasma alpha-synuclein level. Arch Neurol (2010) 1.54
Salivary α-synuclein and DJ-1: potential biomarkers for Parkinson's disease. Brain (2011) 1.53
DJ-1-dependent regulation of oxidative stress in the retinal pigment epithelium (RPE). PLoS One (2013) 1.49
Identification of novel CSF biomarkers for neurodegeneration and their validation by a high-throughput multiplexed targeted proteomic assay. Mol Neurodegener (2015) 1.45
Significance and confounders of peripheral DJ-1 and alpha-synuclein in Parkinson's disease. Neurosci Lett (2010) 1.42
Alpha-synuclein RT-QuIC in the CSF of patients with alpha-synucleinopathies. Ann Clin Transl Neurol (2016) 1.39
Cerebrospinal fluid biomarkers in Parkinson disease. Nat Rev Neurol (2013) 1.37
Phosphorylated α-synuclein in Parkinson's disease. Sci Transl Med (2012) 1.29
Submandibular gland needle biopsy for the diagnosis of Parkinson disease. Neurology (2014) 1.19
α-synuclein reactive antibodies as diagnostic biomarkers in blood sera of Parkinson's disease patients. PLoS One (2011) 1.18
CSF α-synuclein improves diagnostic and prognostic performance of CSF tau and Aβ in Alzheimer's disease. Acta Neuropathol (2013) 1.15
Plasma apolipoprotein A1 as a biomarker for Parkinson disease. Ann Neurol (2013) 1.14
A molecular signature in blood identifies early Parkinson's disease. Mol Neurodegener (2012) 1.13
Low CSF levels of both α-synuclein and the α-synuclein cleaving enzyme neurosin in patients with synucleinopathy. PLoS One (2013) 1.10
Plasma exosomal α-synuclein is likely CNS-derived and increased in Parkinson's disease. Acta Neuropathol (2014) 1.10
Differential role of CSF alpha-synuclein species, tau, and Aβ42 in Parkinson's Disease. Front Aging Neurosci (2014) 1.09
Cerebrospinal fluid α-synuclein predicts cognitive decline in Parkinson disease progression in the DATATOP cohort. Am J Pathol (2014) 1.07
Diagnosis of Parkinson's disease based on disease-specific autoantibody profiles in human sera. PLoS One (2012) 1.06
Complement 3 and factor h in human cerebrospinal fluid in Parkinson's disease, Alzheimer's disease, and multiple-system atrophy. Am J Pathol (2011) 1.04
Biomarker candidates of neurodegeneration in Parkinson's disease for the evaluation of disease-modifying therapeutics. J Neural Transm (Vienna) (2011) 1.04
α-Synuclein in human cerebrospinal fluid is principally derived from neurons of the central nervous system. J Neural Transm (Vienna) (2012) 1.04
A panel of nine cerebrospinal fluid biomarkers may identify patients with atypical parkinsonian syndromes. J Neurol Neurosurg Psychiatry (2015) 1.04
Induction of α-synuclein aggregate formation by CSF exosomes from patients with Parkinson's disease and dementia with Lewy bodies. Brain (2015) 1.03
DJ-1 isoforms in whole blood as potential biomarkers of Parkinson disease. Sci Rep (2012) 1.02
CSF biomarkers and clinical progression of Parkinson disease. Neurology (2014) 1.01
Recent developments in biomarkers in Parkinson disease. Curr Opin Neurol (2013) 1.00
Longitudinal assessment of tau and amyloid beta in cerebrospinal fluid of Parkinson disease. Acta Neuropathol (2013) 1.00
A longitudinal study on α-synuclein in blood plasma as a biomarker for Parkinson's disease. Sci Rep (2013) 0.97
Nilotinib Effects in Parkinson's disease and Dementia with Lewy bodies. J Parkinsons Dis (2016) 0.97
Identification of novel α-synuclein isoforms in human brain tissue by using an online nanoLC-ESI-FTICR-MS method. Neurochem Res (2011) 0.97
α-Synuclein in cerebrospinal fluid of Alzheimer's disease and mild cognitive impairment. J Alzheimers Dis (2013) 0.96
Reduced CSF p-Tau181 to Tau ratio is a biomarker for FTLD-TDP. Neurology (2013) 0.95
Alterations in energy/redox metabolism induced by mitochondrial and environmental toxins: a specific role for glucose-6-phosphate-dehydrogenase and the pentose phosphate pathway in paraquat toxicity. ACS Chem Biol (2014) 0.95
Posiphen as a candidate drug to lower CSF amyloid precursor protein, amyloid-β peptide and τ levels: target engagement, tolerability and pharmacokinetics in humans. J Neurol Neurosurg Psychiatry (2012) 0.95
CSF Apo-E levels associate with cognitive decline and MRI changes. Acta Neuropathol (2014) 0.94
Unbiased approaches to biomarker discovery in neurodegenerative diseases. Neuron (2014) 0.93
Cerebrospinal fluid biomarkers in parkinsonian conditions: an update and future directions. J Neurol Neurosurg Psychiatry (2014) 0.93
The diagnostic value of CSF α-synuclein in the differential diagnosis of dementia with Lewy bodies vs. normal subjects and patients with Alzheimer's disease. PLoS One (2013) 0.92
DJ-1 and αSYN in LRRK2 CSF do not correlate with striatal dopaminergic function. Neurobiol Aging (2011) 0.92
Alpha-synuclein post-translational modifications as potential biomarkers for Parkinson disease and other synucleinopathies. Mol Cell Proteomics (2013) 0.92
Post mortem cerebrospinal fluid α-synuclein levels are raised in multiple system atrophy and distinguish this from the other α-synucleinopathies, Parkinson's disease and Dementia with Lewy bodies. Neurobiol Dis (2011) 0.92
Salivary tau species are potential biomarkers of Alzheimer's disease. J Alzheimers Dis (2011) 0.91
α-Synuclein and mitochondrial dysfunction in Parkinson's disease. Mol Neurobiol (2013) 0.91
Novel one-step immunoassays to quantify α-synuclein: applications for biomarker development and high-throughput screening. J Biol Chem (2012) 0.90
Force control deficits in individuals with Parkinson's disease, multiple systems atrophy, and progressive supranuclear palsy. PLoS One (2013) 0.89
Protein clearance mechanisms of alpha-synuclein and amyloid-Beta in lewy body disorders. Int J Alzheimers Dis (2012) 0.89
CSF tau and tau/Aβ42 predict cognitive decline in Parkinson's disease. Parkinsonism Relat Disord (2015) 0.88
Correlation between decreased CSF α-synuclein and Aβ₁₋₄₂ in Parkinson disease. Neurobiol Aging (2014) 0.88
Blood-based biomarkers for Parkinson's disease. Parkinsonism Relat Disord (2014) 0.88
Altered microRNA profiles in cerebrospinal fluid exosome in Parkinson disease and Alzheimer disease. Oncotarget (2015) 0.87
Biomarkers of Parkinson's disease: current status and future perspectives. Drug Discov Today (2012) 0.86
Premotor biomarkers for Parkinson's disease - a promising direction of research. Transl Neurodegener (2012) 0.86
Gene expression profiling combined with bioinformatics analysis identify biomarkers for Parkinson disease. PLoS One (2012) 0.86
Cerebrospinal fluid biochemical studies in patients with Parkinson's disease: toward a potential search for biomarkers for this disease. Front Cell Neurosci (2014) 0.85
Altered serum IgG levels to α-synuclein in dementia with Lewy bodies and Alzheimer's disease. PLoS One (2013) 0.85
Low levels of cerebrospinal fluid complement 3 and factor H predict faster cognitive decline in mild cognitive impairment. Alzheimers Res Ther (2014) 0.85
Biopsable neural tissues: toward new biomarkers for Parkinson's disease? Front Psychiatry (2010) 0.85
Lower plasma apolipoprotein A1 levels are found in Parkinson's disease and associate with apolipoprotein A1 genotype. Mov Disord (2014) 0.84
Phosphorylated α-synuclein in Parkinson's disease: correlation depends on disease severity. Acta Neuropathol Commun (2015) 0.84
Cerebrospinal fluid peptides as potential Parkinson disease biomarkers: a staged pipeline for discovery and validation. Mol Cell Proteomics (2015) 0.84
Elevated levels of cerebrospinal fluid α-synuclein oligomers in healthy asymptomatic LRRK2 mutation carriers. Front Aging Neurosci (2014) 0.84
Parkinson disease: Progress towards a molecular biomarker for Parkinson disease. Nat Rev Neurol (2010) 0.84
Salivary DJ-1 could be an indicator of Parkinson's disease progression. Front Aging Neurosci (2014) 0.84
Modeling Parkinson's disease in the common marmoset (Callithrix jacchus): overview of models, methods, and animal care. Lab Anim Res (2015) 0.83
The Diagnostic and Differential Diagnosis Utility of Cerebrospinal Fluid α -Synuclein Levels in Parkinson's Disease: A Meta-Analysis. Parkinsons Dis (2015) 0.83
Alpha-Synuclein Expression in Patients with Parkinson's Disease: A Clinician's Perspective. Exp Neurobiol (2013) 0.83
α-Synuclein as CSF and Blood Biomarker of Dementia with Lewy Bodies. Int J Alzheimers Dis (2012) 0.83
Cerebrospinal fluid biomarker candidates for parkinsonian disorders. Front Neurol (2013) 0.83
Variant in the 3' region of SNCA associated with Parkinson's disease and serum α-synuclein levels. J Neurol (2011) 0.82
Saliva α-Synuclein and A High Extinction Coefficient Protein: A Novel Approach in Assessment Biomarkers of Parkinson's Disease. N Am J Med Sci (2014) 0.82
Emerging candidate biomarkers for Parkinson's disease: a review. Aging Dis (2013) 0.82
Plasma apolipoprotein A1 associates with age at onset and motor severity in early Parkinson's disease patients. Mov Disord (2015) 0.82
Park7 interacts with p47(phox) to direct NADPH oxidase-dependent ROS production and protect against sepsis. Cell Res (2015) 0.82
Analysis of alpha-synuclein in malignant melanoma - development of a SRM quantification assay. PLoS One (2014) 0.82
Gender differences in Parkinson's disease: focus on plasma α-synuclein. J Neural Transm (Vienna) (2013) 0.82
Alpha synuclein is transported into and out of the brain by the blood-brain barrier. Peptides (2014) 0.81
Total protein is an effective loading control for cerebrospinal fluid western blots. J Neurosci Methods (2015) 0.81
Proteomics and systems biology: current and future applications in the nutritional sciences. Adv Nutr (2011) 0.81
α-Synuclein and DJ-1 as potential biological fluid biomarkers for Parkinson's Disease. Int J Mol Sci (2010) 0.81
The Concept of Prodromal Parkinson's Disease. J Parkinsons Dis (2015) 0.81
Quantification of CSF biomarkers using an electrochemiluminescence-based detection system in the differential diagnosis of AD and sCJD. J Neurol (2015) 0.80
Associations between Cerebrospinal Fluid Biomarkers and Cognition in Early Untreated Parkinson's Disease. J Parkinsons Dis (2015) 0.80
Oxidized DJ-1 as a possible biomarker of Parkinson's disease. J Clin Biochem Nutr (2014) 0.80
Increased α-synuclein levels in the cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. J Neurol (2014) 0.79
Targeted discovery and validation of plasma biomarkers of Parkinson's disease. J Proteome Res (2014) 0.79
Biomarkers of the dementia. Int J Alzheimers Dis (2011) 0.79
What is the Clinical Significance of Cerebrospinal Fluid Biomarkers in Parkinson's disease? Is the Significance Diagnostic or Prognostic? Exp Neurobiol (2014) 0.79
A consensus in Korea regarding a protocol to reduce preanalytical sources of variability in the measurement of the cerebrospinal fluid biomarkers of Alzheimer's disease. J Clin Neurol (2015) 0.79
Iron and Oxidative Stress in Parkinson's Disease: An Observational Study of Injury Biomarkers. PLoS One (2016) 0.79
Do CSF levels of t-Tau, p-Tau and β₁₋₄₂ amyloid correlate with dopaminergic system impairment in patients with a clinical diagnosis of Parkinson disease? A ¹²³I-FP-CIT study in the early stages of the disease. Eur J Nucl Med Mol Imaging (2014) 0.79
Development of an ultra-high sensitive immunoassay with plasma biomarker for differentiating Parkinson disease dementia from Parkinson disease using antibody functionalized magnetic nanoparticles. J Nanobiotechnology (2016) 0.78
Specific changes of serum proteins in Parkinson's disease patients. PLoS One (2014) 0.78
Altered Plasma Profile of Antioxidant Proteins as an Early Correlate of Pancreatic β Cell Dysfunction. J Biol Chem (2016) 0.78
Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging (2002) 22.40
Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol (2006) 9.99
Levodopa and the progression of Parkinson's disease. N Engl J Med (2004) 5.44
Multiplexed particle-based flow cytometric assays. J Immunol Methods (2000) 5.09
Detection of oligomeric forms of alpha-synuclein protein in human plasma as a potential biomarker for Parkinson's disease. FASEB J (2006) 2.96
Validation and comparison of luminex multiplex cytokine analysis kits with ELISA: determinations of a panel of nine cytokines in clinical sample culture supernatants. J Reprod Immunol (2005) 2.70
Oxidative damage of DJ-1 is linked to sporadic Parkinson and Alzheimer diseases. J Biol Chem (2006) 2.50
Synucleinopathies: clinical and pathological implications. Arch Neurol (2001) 2.36
Direct quantification of CSF alpha-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration. Exp Neurol (2008) 2.31
Decreased alpha-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson's disease. Biochem Biophys Res Commun (2006) 2.27
Full length alpha-synuclein is present in cerebrospinal fluid from Parkinson's disease and normal subjects. Neurosci Lett (2000) 1.98
Proteasomal inhibition by alpha-synuclein filaments and oligomers. J Biol Chem (2004) 1.84
Progressive supranuclear palsy: where are we now? Lancet Neurol (2002) 1.65
Alpha-synuclein and Parkinson's disease. Cell Mol Life Sci (2000) 1.63
Cerebrospinal fluid alpha-synuclein in neurodegenerative disorders-a marker of synapse loss? Neurosci Lett (2008) 1.60
Dissembled DJ-1 high molecular weight complex in cortex mitochondria from Parkinson's disease patients. Mol Neurodegener (2009) 1.52
Beta-amlyoid 1-42 and tau-protein in cerebrospinal fluid of patients with Parkinson's disease dementia. Dement Geriatr Cogn Disord (2006) 1.49
Increased level of DJ-1 in the cerebrospinal fluids of sporadic Parkinson's disease. Biochem Biophys Res Commun (2006) 1.45
The plasma alpha-synuclein levels in patients with Parkinson's disease and multiple system atrophy. J Neural Transm (Vienna) (2006) 1.33
Plasma alpha-synuclein is decreased in subjects with Parkinson's disease. Exp Neurol (2006) 1.23
Secretion of DJ-1 into the serum of patients with Parkinson's disease. Neurosci Lett (2007) 1.15
Skin and platelet alpha-synuclein as peripheral biomarkers of Parkinson's disease. Neurosci Lett (2005) 1.15
Cerebrospinal fluid alpha-synuclein does not discriminate between dementia disorders. J Alzheimers Dis (2009) 1.11
DJ-1 is present in a large molecular complex in human brain tissue and interacts with alpha-synuclein. J Neurochem (2005) 1.08
Plasma levels of DJ-1 as a possible marker for progression of sporadic Parkinson's disease. Neurosci Lett (2007) 1.05
Cerebellar alpha-synuclein levels are decreased in Parkinson's disease and do not correlate with SNCA polymorphisms associated with disease in a Swedish material. FASEB J (2008) 1.04
Determination of alpha-synuclein concentration in human plasma using ELISA. Scand J Clin Lab Invest (2007) 1.03
Localization of dopamine receptor subtypes in systemic arteries. Clin Exp Hypertens (2000) 0.97
Predominant release of lysosomal enzymes by newborn rat microglia after LPS treatment revealed by proteomic studies. J Proteome Res (2008) 0.94
Identification of novel proteins affected by rotenone in mitochondria of dopaminergic cells. BMC Neurosci (2007) 0.94
Platelet alpha- and gamma-synucleins in Parkinson's disease and normal control subjects. J Alzheimers Dis (2002) 0.93
A more efficient enzyme-linked immunosorbent assay for measurement of alpha-synuclein in cerebrospinal fluid. J Neurosci Methods (2007) 0.92
Phosphoproteome study reveals Hsp27 as a novel signaling molecule involved in GDNF-induced neurite outgrowth. J Proteome Res (2009) 0.91
Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement (2011) 24.02
Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol (2007) 18.62
Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med (2005) 12.04
Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet (2011) 10.07
Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain (2011) 9.90
Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord (2008) 9.52
Revising the definition of Alzheimer's disease: a new lexicon. Lancet Neurol (2010) 8.74
The Uniform Data Set (UDS): clinical and cognitive variables and descriptive data from Alzheimer Disease Centers. Alzheimer Dis Assoc Disord (2006) 8.04
Interferon regulatory factor 6 (IRF6) gene variants and the risk of isolated cleft lip or palate. N Engl J Med (2004) 7.91
Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nat Med (2007) 6.80
Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. Lancet Neurol (2008) 6.76
The ageing systemic milieu negatively regulates neurogenesis and cognitive function. Nature (2011) 6.71
Astrocytic purinergic signaling coordinates synaptic networks. Science (2005) 6.55
Essential roles of PI(3)K-p110beta in cell growth, metabolism and tumorigenesis. Nature (2008) 6.04
A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N Engl J Med (2009) 5.81
A QTL for rice grain width and weight encodes a previously unknown RING-type E3 ubiquitin ligase. Nat Genet (2007) 5.70
Single-cell exome sequencing reveals single-nucleotide mutation characteristics of a kidney tumor. Cell (2012) 5.62
Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions. Nat Genet (2010) 5.52
The Alzheimer's Disease Centers' Uniform Data Set (UDS): the neuropsychologic test battery. Alzheimer Dis Assoc Disord (2009) 5.50
TARDBP mutations in amyotrophic lateral sclerosis with TDP-43 neuropathology: a genetic and histopathological analysis. Lancet Neurol (2008) 5.33
National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimers Dement (2012) 5.10
Phenomenology and classification of dystonia: a consensus update. Mov Disord (2013) 4.98
Glucose levels and risk of dementia. N Engl J Med (2013) 4.95
Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial. Arch Neurol (2011) 4.76
Common genetic variation in the HLA region is associated with late-onset sporadic Parkinson's disease. Nat Genet (2010) 4.47
Pathological correlates of dementia in a longitudinal, population-based sample of aging. Ann Neurol (2007) 4.47
Comprehensive research synopsis and systematic meta-analyses in Parkinson's disease genetics: The PDGene database. PLoS Genet (2012) 4.27
Development and characterization of gemcitabine-resistant pancreatic tumor cells. Ann Surg Oncol (2007) 4.12
New world bats harbor diverse influenza A viruses. PLoS Pathog (2013) 4.10
Early repolarization pattern and risk for arrhythmia death: a meta-analysis. J Am Coll Cardiol (2013) 4.03
An emerging recombinant human enterovirus 71 responsible for the 2008 outbreak of hand foot and mouth disease in Fuyang city of China. Virol J (2010) 3.90
Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Process, format, and clinimetric testing plan. Mov Disord (2007) 3.86
Antagonistic regulation of PIN phosphorylation by PP2A and PINOID directs auxin flux. Cell (2007) 3.84
Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurol (2010) 3.84
Rapid growth of a hepatocellular carcinoma and the driving mutations revealed by cell-population genetic analysis of whole-genome data. Proc Natl Acad Sci U S A (2011) 3.80
Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol (2012) 3.77
Primary age-related tauopathy (PART): a common pathology associated with human aging. Acta Neuropathol (2014) 3.75
Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses? Arch Neurol (2003) 3.75
Meta-analysis of genome-wide association studies of asthma in ethnically diverse North American populations. Nat Genet (2011) 3.68
Aggregated alpha-synuclein activates microglia: a process leading to disease progression in Parkinson's disease. FASEB J (2005) 3.60
Co-morbidity of TDP-43 proteinopathy in Lewy body related diseases. Acta Neuropathol (2007) 3.55
Mice genetically deficient in vasopressin V1a and V1b receptors are resistant to jet lag. Science (2013) 3.51
Mitochondrial polymorphisms significantly reduce the risk of Parkinson disease. Am J Hum Genet (2003) 3.39
Biological markers for therapeutic trials in Alzheimer's disease. Proceedings of the biological markers working group; NIA initiative on neuroimaging in Alzheimer's disease. Neurobiol Aging (2003) 2.96
Meta-analysis confirms CR1, CLU, and PICALM as alzheimer disease risk loci and reveals interactions with APOE genotypes. Arch Neurol (2010) 2.91
Age at onset in two common neurodegenerative diseases is genetically controlled. Am J Hum Genet (2002) 2.90
R428, a selective small molecule inhibitor of Axl kinase, blocks tumor spread and prolongs survival in models of metastatic breast cancer. Cancer Res (2010) 2.87
The role of biomarkers in clinical trials for Alzheimer disease. Alzheimer Dis Assoc Disord (2006) 2.86
A parallel group placebo controlled study of prazosin for trauma nightmares and sleep disturbance in combat veterans with post-traumatic stress disorder. Biol Psychiatry (2006) 2.85
A trial of prazosin for combat trauma PTSD with nightmares in active-duty soldiers returned from Iraq and Afghanistan. Am J Psychiatry (2013) 2.84
Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. Ann Neurol (2011) 2.84
Movement disorders in cerebrovascular disease. Lancet Neurol (2013) 2.81
Age and apolipoprotein E*4 allele effects on cerebrospinal fluid beta-amyloid 42 in adults with normal cognition. Arch Neurol (2006) 2.79
Patient selection and assessment recommendations for deep brain stimulation in Tourette syndrome. Mov Disord (2006) 2.72
Gliosis and brain remodeling after treatment of stroke in rats with marrow stromal cells. Glia (2005) 2.68
Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study. Ann Neurol (2010) 2.67
Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria. Lancet Neurol (2009) 2.60
Reduction of nightmares and other PTSD symptoms in combat veterans by prazosin: a placebo-controlled study. Am J Psychiatry (2003) 2.59
Targeting SRC family kinases inhibits growth and lymph node metastases of prostate cancer in an orthotopic nude mouse model. Cancer Res (2008) 2.59
HIF-1alpha, STAT3, CBP/p300 and Ref-1/APE are components of a transcriptional complex that regulates Src-dependent hypoxia-induced expression of VEGF in pancreatic and prostate carcinomas. Oncogene (2005) 2.53
MicroRNA identification based on sequence and structure alignment. Bioinformatics (2005) 2.52
ABP1 mediates auxin inhibition of clathrin-dependent endocytosis in Arabidopsis. Cell (2010) 2.51
Subthalamic deep brain stimulation with a constant-current device in Parkinson's disease: an open-label randomised controlled trial. Lancet Neurol (2012) 2.50
Characterization of the Huntington intermediate CAG repeat expansion phenotype in PHAROS. Neurology (2013) 2.45
Approaches for high internal quantum efficiency green InGaN light-emitting diodes with large overlap quantum wells. Opt Express (2011) 2.44
Diagnostic criteria for the behavioral variant of frontotemporal dementia (bvFTD): current limitations and future directions. Alzheimer Dis Assoc Disord (2007) 2.43
Rosiglitazone attenuates learning and memory deficits in Tg2576 Alzheimer mice. Exp Neurol (2006) 2.42
Subcellular homeostasis of phytohormone auxin is mediated by the ER-localized PIN5 transporter. Nature (2009) 2.40
mdmx is a negative regulator of p53 activity in vivo. Cancer Res (2002) 2.40
CSF multianalyte profile distinguishes Alzheimer and Parkinson diseases. Am J Clin Pathol (2008) 2.34
Autopsy-proven Huntington's disease with 29 trinucleotide repeats. Mov Disord (2007) 2.34
The role of autophagy-lysosome pathway in neurodegeneration associated with Parkinson's disease. Brain (2008) 2.34
Age-varying association between statin use and incident Alzheimer's disease. J Am Geriatr Soc (2010) 2.34
In vitro derivation of functional insulin-producing cells from human embryonic stem cells. Cell Res (2007) 2.28
Genome-wide gene-environment study identifies glutamate receptor gene GRIN2A as a Parkinson's disease modifier gene via interaction with coffee. PLoS Genet (2011) 2.28
Mutations in NR4A2 associated with familial Parkinson disease. Nat Genet (2002) 2.27
Genome-wide association study implicates chromosome 9q21.31 as a susceptibility locus for asthma in mexican children. PLoS Genet (2009) 2.27